Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis
LA Linkins, PT Choi, JD Douketis - Annals of internal medicine, 2003 - acpjournals.org
… because these studies did not focus on patients with venous thromboembolism (18-22), …
patients with venous thromboembolism who received at least 3 months of oral anticoagulant …
patients with venous thromboembolism who received at least 3 months of oral anticoagulant …
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with …
D Farge, H Bounameaux, B Brenner… - The Lancet …, 2016 - thelancet.com
Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer.
These patients are at an increased risk of developing VTE and are more likely to have a …
These patients are at an increased risk of developing VTE and are more likely to have a …
[HTML][HTML] … ‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism …
… 9 ; (2) patients were to receive oral anticoagulant therapy with an … anticoagulation; and (3)
recurrent VTE (as defined by the study authors) was reported during extended anticoagulation…
recurrent VTE (as defined by the study authors) was reported during extended anticoagulation…
Evolving use of new oral anticoagulants for treatment of venous thromboembolism
… new oral anticoagulants (NOACs), which can be given in fixed doses and produce such a
predictable anticoagulant … all-oral regimens, which can replace parenteral anticoagulants and …
predictable anticoagulant … all-oral regimens, which can replace parenteral anticoagulants and …
… oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism
CB Granger, LV Armaganijan - Circulation, 2012 - Am Heart Assoc
… We will present the case that the new oral anticoagulants provide major advantages to
warfarin that should make them first-line agents to prevent thromboembolism in patients with AF …
warfarin that should make them first-line agents to prevent thromboembolism in patients with AF …
Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis
A Gómez-Outes, AI Terleira-Fernández… - Thrombosis research, 2014 - Elsevier
… We systematically reviewed and meta-analysed clinical outcomes with direct oral anticoagulants
(DOAC: dabigatran, rivaroxaban, apixaban or edoxaban) for treatment of acute VTE. …
(DOAC: dabigatran, rivaroxaban, apixaban or edoxaban) for treatment of acute VTE. …
Oral anticoagulant therapy in venous thromboembolism
B Cosmi, G Palareti - Seminars in Vascular Medicine, 2003 - thieme-connect.com
… In patients with VTE and cancer, oral anticoagulation poses a higher risk of bleeding, and
such patients are more prone to recurrences. Alternative treatment with LMWH could be safer …
such patients are more prone to recurrences. Alternative treatment with LMWH could be safer …
Oral anticoagulant therapy for venous thromboembolism
DL Diuguid - New England Journal of Medicine, 1997 - Mass Medical Soc
… Studies that focus on patients with temporary risk factors (such as surgery, pregnancy, or …
periods of oral anticoagulant therapy are sufficient to prevent recurrent thromboembolic disease…
periods of oral anticoagulant therapy are sufficient to prevent recurrent thromboembolic disease…
The duration of oral anticoagulant therapy after a second episode of venous thromboembolism
, … of Anticoagulation Trial Study Group - … England Journal of …, 1997 - Mass Medical Soc
… , we compared six months of oral anticoagulant therapy with anticoagulant therapy continued
indefinitely in patients who had had a second episode of venous thromboembolism. Of 227 …
indefinitely in patients who had had a second episode of venous thromboembolism. Of 227 …
Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve Bioprosthesis
R Philippart, A Brunet-Bernard… - Thrombosis and …, 2016 - thieme-connect.com
… In current treatment guidelines, patients with ‘non valvular’ AF and a CHA2DS2-VASc … oral
anticoagulation, whether with a vitamin K antagonist (VKA) or a non-VKA oral anticoagulant (…
anticoagulation, whether with a vitamin K antagonist (VKA) or a non-VKA oral anticoagulant (…
相关搜索
- newer oral anticoagulants thromboembolism in patients
- direct oral anticoagulants thromboembolism treatment
- direct oral anticoagulants venous thromboembolism
- oral anticoagulant therapy venous thromboembolism
- direct oral anticoagulants vitamin k antagonists
- extended oral anticoagulant therapy
- safety of novel oral anticoagulants
- direct oral anticoagulants meta analysis
- atrial fibrillation thromboembolism in patients
- management of oral anticoagulants venous thromboembolism
- direct oral anticoagulants atrial fibrillation
- first line agents thromboembolism in patients
- direct oral anticoagulants focus on patients
- oral anticoagulant treatment venous thromboembolism
- non-vitamin k antagonist oral anticoagulants
- oral anticoagulant treatment in patients